Shanghai, China, April 28, 2025—Shanghai Novamab Biomedical Technology Co., Ltd. ("Novamab"), a biotechnology company dedicated to pioneering nanobody-based therapeutics, announced today its participation in the 2025 Digestive Disease Week (DDW), taking place from May 3 to 6 (local time) in San Diego, California. At the conference, Novamab will present breakthrough advancements in the treatment of inflammatory bowel disease (IBD), including the development of an oral TL1A nanobody and a long-acting TL1A bispecific antibody. These innovative therapies utilize proprietary TL1A-targeting nanobody technology to precisely address the pathological mechanisms of IBD.

Highlights include: 

• Oral TL1A Nanobody: A groundbreaking solution that resists intestinal degradation, ensuring high gut distribution with minimal systemic exposure.

• Long-Acting BsAbs/TsAbs: Innovative TL1A/IL-23, TL1A/α4β7, and TL1A/IL-23/α4β7, targeting multiple IBD pathways for greater efficacy and convenience.

About DDW 2025

The 2025 Digestive Disease Week (DDW) will be held from May 3 to 6 in San Diego, California. As the world’s largest and most prestigious conference in gastroenterology, DDW is jointly organized by four leading medical societies: the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases (AASLD), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT). The event spans all aspects of digestive disease research and clinical practice, attracting approximately 15,000 global physicians, researchers, and scholars annually. World-renowned experts will delve into the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Shanghai Novamab Biomedical Technology Co., Ltd. is an innovative biopharmaceutical company dedicated to the research, development, and commercialization of VHH therapeutics. Founded in October 2017 and located in the Shanghai International Medical Park, the company has established a comprehensive platform covering R&D, CMC, and pilot-scale manufacturing, and operates China’s first 500-L Pichia pastoris VHH GMP pilot production facility. Novamab is currently the only company in China with full-process development capabilities for VHHs. As of March 2025, Novamab has filed over 80 domestic and international invention patents, with 31 patents granted. Its product pipeline spans respiratory, autoimmune indications, and it has secured four clinical trial authorizations. Notably, both LQ036 and LQ043H—targeting the same pathway—represent the world’s first inhaled VHH therapeutics and have the potential to revolutionize the treatment of respiratory diseases.